Cargando…

Impact of latency‐reversing agents on human macrophage physiology

INTRODUCTION: HIV‐1 eradication is hindered by the presence of inducible long‐lived reservoirs of latently infected cells which rapidly disseminate viral particles upon treatment interruption. Eliminating these reservoirs by the so‐called shock and kill strategy represents a crucial concept toward a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hany, Laurent, Turmel, Marc‐Olivier, Barat, Corinne, Ouellet, Michel, Tremblay, Michel J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9753817/ https://www.ncbi.nlm.nih.gov/pubmed/36480653 http://dx.doi.org/10.1002/iid3.590

Ejemplares similares

Contrasting effect of the latency-reversing agents bryostatin-1 and JQ1 on astrocyte-mediated neuroinflammation and brain neutrophil invasion
por: Proust, Alizé, et al.
Publicado: (2017)

HIV-1 Promotes Intake of Leishmania Parasites by Enhancing Phosphatidylserine-Mediated, CD91/LRP-1-Dependent Phagocytosis in Human Macrophages
por: Lodge, Robert, et al.
Publicado: (2012)

Leishmania infantum Amastigotes Enhance HIV-1 Production in Cocultures of Human Dendritic Cells and CD4(+) T Cells by Inducing Secretion of IL-6 and TNF-α
por: Garg, Ravendra, et al.
Publicado: (2009)

Leishmania infantum Amastigotes Trigger a Subpopulation of Human B Cells with an Immunoregulatory Phenotype
por: Andreani, Guadalupe, et al.
Publicado: (2015)

Global Mapping of the Macrophage-HIV-1 Transcriptome Reveals that Productive Infection Induces Remodeling of Host Cell DNA and Chromatin
por: Deshiere, Alexandre, et al.
Publicado: (2017)

Latency Reversing Agents: Kick and Kill of HTLV-1?
por: Schnell, Annika P., et al.
Publicado: (2021)

Ongoing Clinical Trials of Human Immunodeficiency Virus Latency-Reversing and Immunomodulatory Agents
por: Delagrèverie, Héloïse M., et al.
Publicado: (2016)

NSC95397 is a Novel HIV Latency Reversing Agent
por: Nichols Doyle, Randilea, et al.
Publicado: (2023)

Sensing of HIV-1 by TLR8 activates human T cells and reverses latency
por: Meås, Hany Zekaria, et al.
Publicado: (2020)

Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agents
por: Marsden, Matthew D., et al.
Publicado: (2018)

HIV latency reversing agents act through Tat post translational modifications
por: Khoury, Georges, et al.
Publicado: (2018)

Identification of functional microRNAs released through asymmetrical processing of HIV-1 TAR element(†)
por: Ouellet, Dominique L., et al.
Publicado: (2008)

Diverse Impacts of HIV Latency-Reversing Agents on CD8+ T-Cell Function: Implications for HIV Cure
por: Clutton, Genevieve Tyndale, et al.
Publicado: (2018)

Microarray study reveals that HIV-1 induces rapid type-I interferon-dependent p53 mRNA up-regulation in human primary CD4(+ )T cells
por: Imbeault, Michaël, et al.
Publicado: (2009)

Current Status of Latency Reversing Agents Facing the Heterogeneity of HIV-1 Cellular and Tissue Reservoirs
por: Ait-Ammar, Amina, et al.
Publicado: (2020)

HIV-1 Latency and Latency Reversal: Does Subtype Matter?
por: Sarabia, Indra, et al.
Publicado: (2019)

Impact of IL-15 and latency reversing agent combinations in the reactivation and NK cell-mediated suppression of the HIV reservoir
por: Covino, Daniela Angela, et al.
Publicado: (2022)

Structure-Activity Relationship Analysis of Benzotriazine Analogues as HIV-1 Latency-Reversing Agents
por: Sorensen, Eric S., et al.
Publicado: (2020)

Extracellular ATP reduces HIV-1 transfer from immature dendritic cells to CD4(+ )T lymphocytes
por: Barat, Corinne, et al.
Publicado: (2008)

Leukotrienes inhibit early stages of HIV-1 infection in monocyte-derived microglia-like cells
por: Bertin, Jonathan, et al.
Publicado: (2012)

Interactions between prostaglandins, leukotrienes and HIV-1: Possible implications for the central nervous system
por: Bertin, Jonathan, et al.
Publicado: (2012)

New Concepts in Therapeutic Manipulation of HIV-1 Transcription and Latency: Latency Reversal versus Latency Prevention
por: Lewis, Catherine A., et al.
Publicado: (2023)

HIV Latency-Reversing Agents Have Diverse Effects on Natural Killer Cell Function
por: Garrido, Carolina, et al.
Publicado: (2016)

Trade-off between synergy and efficacy in combinations of HIV-1 latency-reversing agents
por: Gupta, Vipul, et al.
Publicado: (2018)

Latency reversal agents modulate HIV antigen processing and presentation to CD8 T cells
por: Boucau, Julie, et al.
Publicado: (2020)

Harmine enhances the activity of the HIV-1 latency-reversing agents ingenol A and SAHA
por: Taylor, Jared P., et al.
Publicado: (2020)

Discovering the Mechanisms of Oleodaphnone as a Potential HIV Latency-Reversing Agent by Transcriptome Profiling
por: Li, Shifei, et al.
Publicado: (2023)

Epigenetic Regulation of HIV-1 Sense and Antisense Transcription in Response to Latency-Reversing Agents
por: Li, Rui, et al.
Publicado: (2023)

The differential short- and long-term effects of HIV-1 latency-reversing agents on T cell function
por: Clutton, G., et al.
Publicado: (2016)

Latency reversal agents affect differently the latent reservoir present in distinct CD4(+) T subpopulations
por: Grau-Expósito, Judith, et al.
Publicado: (2019)

Thalidomide as a Potential HIV Latency Reversal Agent: Is It the Right Time to Forget the Ancestral Sins?
por: Vignesh, Ramachandran, et al.
Publicado: (2017)

Polyanionic carbosilane dendrimers as a new adjuvant in combination with latency reversal agents for HIV treatment
por: Relaño-Rodríguez, Ignacio, et al.
Publicado: (2019)

New Latency Reversing Agents for HIV-1 Cure: Insights from Nonhuman Primate Models
por: Bricker, Katherine M., et al.
Publicado: (2021)

Identification of celastrol as a novel HIV-1 latency reversal agent by an image-based screen
por: Liu, Hongbing, et al.
Publicado: (2021)

Are BET Inhibitors yet Promising Latency-Reversing Agents for HIV-1 Reactivation in AIDS Therapy?
por: Salahong, Thanarat, et al.
Publicado: (2021)

The latency-reversing agent HODHBt synergizes with IL-15 to enhance cytotoxic function of HIV-specific T cells
por: Copertino, Dennis C., et al.
Publicado: (2023)

HIV-1 Latency in Monocytes/Macrophages
por: Kumar, Amit, et al.
Publicado: (2014)

Reversible Human Immunodeficiency Virus Type-1 Latency in Primary Human Monocyte-Derived Macrophages Induced by Sustained M1 Polarization
por: Graziano, Francesca, et al.
Publicado: (2018)

Corrigendum: The differential short- and long-term effects of HIV-1 latency-reversing agents on T cell function
por: Clutton, G., et al.
Publicado: (2016)

Identification of Novel HIV-1 Latency-Reversing Agents from a Library of Marine Natural Products
por: Richard, Khumoekae, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_4vqu4a9kc5un0edepufeq7hvnf